You would have to think that Trofinetide potential for disease modifying is head and shoulders a better option (if successful) than a drug focused on managing seizures only. Complimentary at least. Or are you talking about the fact they are both competing for trial participants?
Head to head, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.66 |
Change
0.050(0.37%) |
Mkt cap ! $1.763B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $13.85 | $13.51 | $991.6K | 72.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 475 | $13.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 141 | 8 |
View Market Depth
| Last trade - 11.48am 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |